Literature DB >> 24560919

Colistin/daptomycin: an unconventional antimicrobial combination synergistic in vitro against multidrug-resistant Acinetobacter baumannii.

Irene Galani1, Konstantina Orlandou1, Helen Moraitou2, George Petrikkos1, Maria Souli3.   

Abstract

The in vitro activity of the combination colistin/daptomycin was evaluated against multidrug-resistant Acinetobacter baumannii clinical isolates. Clonal relationships were assessed by pulsed-field gel electrophoresis. The following synergy studies were undertaken: (i) daptomycin MICs were determined by E-test on Mueller-Hinton agar plates supplemented with a subinhibitory concentration of colistin; and (ii) time-kill methodology using tubes containing an inoculum of 5×10(5)CFU/mL and subinhibitory concentrations of each antibiotic alone or in combination subcultured at 0, 5 and 24h for colony counting. Synergy was defined as ≥2log10CFU/mL decrease of viable colonies compared with colistin alone. Ten colistin-susceptible and four colistin-resistant A. baumannii isolates were tested. Isolates were assigned to nine different clonal types. Enhanced in vitro activity of the combination was detected only against colistin-susceptible isolates; using plates supplemented with colistin, the daptomycin MIC was reduced by 4- to 128-fold. From a total of 30 isolate-concentration combinations in time-kill studies, a synergistic interaction was detected in 16 (53.3%). The combination exhibited synergy against 8 and 12 of these combinations at 5h and 24h, respectively. No antagonism was detected. Colistin alone was bactericidal against two colistin-susceptible isolates at 24h, whereas the combination was bactericidal against 9 colistin-susceptible isolates at 24h. Against all colistin-resistant isolates, the combination exhibited a static effect and indifference in time-kill studies. Potent in vitro synergistic interactions between colistin and daptomycin provide evidence that this unorthodox combination may be beneficial in the treatment of colistin-susceptible multidrug-resistant A. baumannii.
Copyright © 2014. Published by Elsevier B.V.

Entities:  

Keywords:  Lipopeptides; Polymyxins; Synergy

Mesh:

Substances:

Year:  2014        PMID: 24560919     DOI: 10.1016/j.ijantimicag.2013.12.010

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  19 in total

1.  In vitro activity of fosfomycin in combination with colistin against clinical isolates of carbapenem-resistant Pseudomas aeruginosa.

Authors:  Xiuzhen Di; Rui Wang; Bin Liu; Xin Zhang; Wentao Ni; Jin Wang; Beibei Liang; Yun Cai; Youning Liu
Journal:  J Antibiot (Tokyo)       Date:  2015-03-25       Impact factor: 2.649

2.  Task force on management and prevention of Acinetobacter baumannii infections in the ICU.

Authors:  José Garnacho-Montero; George Dimopoulos; Garyphallia Poulakou; Murat Akova; José Miguel Cisneros; Jan De Waele; Nicola Petrosillo; Harald Seifert; Jean François Timsit; Jordi Vila; Jean-Ralph Zahar; Matteo Bassetti
Journal:  Intensive Care Med       Date:  2015-10-05       Impact factor: 17.440

Review 3.  Insights into Newer Antimicrobial Agents Against Gram-negative Bacteria.

Authors:  Neelam Taneja; Harsimran Kaur
Journal:  Microbiol Insights       Date:  2016-03-20

Review 4.  Synergistic combinations of polymyxins.

Authors:  Justin R Lenhard; Roger L Nation; Brian T Tsuji
Journal:  Int J Antimicrob Agents       Date:  2016-10-24       Impact factor: 5.283

5.  Can Plazomicin Alone or in Combination Be a Therapeutic Option against Carbapenem-Resistant Acinetobacter baumannii?

Authors:  Cristina García-Salguero; Iciar Rodríguez-Avial; Juan J Picazo; Esther Culebras
Journal:  Antimicrob Agents Chemother       Date:  2015-07-13       Impact factor: 5.191

6.  Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii.

Authors:  Dana R Bowers; Henry Cao; Jian Zhou; Kimberly R Ledesma; Dongxu Sun; Olga Lomovskaya; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2015-02-23       Impact factor: 5.191

Review 7.  In search for a synergistic combination against pandrug-resistant A. baumannii; methodological considerations.

Authors:  Stamatis Karakonstantis; Petros Ioannou; Diamantis D Kofteridis
Journal:  Infection       Date:  2022-01-04       Impact factor: 3.553

Review 8.  Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections.

Authors:  J Alexander Viehman; M Hong Nguyen; Yohei Doi
Journal:  Drugs       Date:  2014-08       Impact factor: 9.546

9.  In Vitro Activities of Novel Antimicrobial Combinations against Extensively Drug-Resistant Acinetobacter baumannii.

Authors:  J Córdoba; N M Coronado-Álvarez; D Parra; J Parra-Ruiz
Journal:  Antimicrob Agents Chemother       Date:  2015-09-14       Impact factor: 5.191

Review 10.  Losing the Battle but Winning the War: Can Defeated Antibacterials Form Alliances to Combat Drug-Resistant Pathogens?

Authors:  Song Oh; Raymond Chau; Anh T Nguyen; Justin R Lenhard
Journal:  Antibiotics (Basel)       Date:  2021-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.